622 related articles for article (PubMed ID: 14612497)
21. Tissue factor pathway inhibitor 2 (TFPI2) is frequently silenced by aberrant promoter hypermethylation in gastric cancer.
Takada H; Wakabayashi N; Dohi O; Yasui K; Sakakura C; Mitsufuji S; Taniwaki M; Yoshikawa T
Cancer Genet Cytogenet; 2010 Feb; 197(1):16-24. PubMed ID: 20113832
[TBL] [Abstract][Full Text] [Related]
22. Frequent epigenetic inactivation of Wnt inhibitory factor-1 in human gastrointestinal cancers.
Taniguchi H; Yamamoto H; Hirata T; Miyamoto N; Oki M; Nosho K; Adachi Y; Endo T; Imai K; Shinomura Y
Oncogene; 2005 Nov; 24(53):7946-52. PubMed ID: 16007117
[TBL] [Abstract][Full Text] [Related]
23. XIAP-associated factor 1 (XAF1), a novel target of p53, enhances p53-mediated apoptosis via post-translational modification.
Zou B; Chim CS; Pang R; Zeng H; Dai Y; Zhang R; Lam CS; Tan VP; Hung IF; Lan HY; Wong BC
Mol Carcinog; 2012 May; 51(5):422-32. PubMed ID: 21678496
[TBL] [Abstract][Full Text] [Related]
24. XAF1 mediates apoptosis through an extracellular signal-regulated kinase pathway in colon cancer.
Yu LF; Wang J; Zou B; Lin MC; Wu YL; Xia HH; Sun YW; Gu Q; He H; Lam SK; Kung HF; Wong BC
Cancer; 2007 May; 109(10):1996-2003. PubMed ID: 17385215
[TBL] [Abstract][Full Text] [Related]
25. Promoter hypermethylation of cyclooxygenase-2 in gastric carcinoma.
Yu J; Leung WK; Lee TL; Tse PC; To KF; Sung JJ
Int J Oncol; 2003 May; 22(5):1025-31. PubMed ID: 12684668
[TBL] [Abstract][Full Text] [Related]
26. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
Yuan J; Luo RZ; Fujii S; Wang L; Hu W; Andreeff M; Pan Y; Kadota M; Oshimura M; Sahin AA; Issa JP; Bast RC; Yu Y
Cancer Res; 2003 Jul; 63(14):4174-80. PubMed ID: 12874023
[TBL] [Abstract][Full Text] [Related]
27. Biallelic epigenetic inactivation of the RASSF1A tumor suppressor gene in medulloblastoma development.
Lusher ME; Lindsey JC; Latif F; Pearson AD; Ellison DW; Clifford SC
Cancer Res; 2002 Oct; 62(20):5906-11. PubMed ID: 12384556
[TBL] [Abstract][Full Text] [Related]
28. Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma.
Schagdarsurengin U; Gimm O; Hoang-Vu C; Dralle H; Pfeifer GP; Dammann R
Cancer Res; 2002 Jul; 62(13):3698-701. PubMed ID: 12097277
[TBL] [Abstract][Full Text] [Related]
29. Transcriptional silencing of the DLC-1 tumor suppressor gene by epigenetic mechanism in gastric cancer cells.
Kim TY; Jong HS; Song SH; Dimtchev A; Jeong SJ; Lee JW; Kim TY; Kim NK; Jung M; Bang YJ
Oncogene; 2003 Jun; 22(25):3943-51. PubMed ID: 12813468
[TBL] [Abstract][Full Text] [Related]
30. Promoter hypermethylation and silencing of CHFR mitotic stress checkpoint gene in human gastric cancers.
Kang HC; Kim IJ; Park JH; Shin Y; Park HW; Ku JL; Yang HK; Lee KU; Choe KJ; Park JG
Oncol Rep; 2004 Jul; 12(1):129-33. PubMed ID: 15201973
[TBL] [Abstract][Full Text] [Related]
31. Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma.
Tomizawa Y; Kohno T; Kondo H; Otsuka A; Nishioka M; Niki T; Yamada T; Maeshima A; Yoshimura K; Saito R; Minna JD; Yokota J
Clin Cancer Res; 2002 Jul; 8(7):2362-8. PubMed ID: 12114441
[TBL] [Abstract][Full Text] [Related]
32. Inactivation of RAS association domain family 1A gene in cervical carcinomas and the role of human papillomavirus infection.
Kuzmin I; Liu L; Dammann R; Geil L; Stanbridge EJ; Wilczynski SP; Lerman MI; Pfeifer GP
Cancer Res; 2003 Apr; 63(8):1888-93. PubMed ID: 12702579
[TBL] [Abstract][Full Text] [Related]
33. Epigenetic down-regulation and suppressive role of DCBLD2 in gastric cancer cell proliferation and invasion.
Kim M; Lee KT; Jang HR; Kim JH; Noh SM; Song KS; Cho JS; Jeong HY; Kim SY; Yoo HS; Kim YS
Mol Cancer Res; 2008 Feb; 6(2):222-30. PubMed ID: 18314483
[TBL] [Abstract][Full Text] [Related]
34. SLIT2, a human homologue of the Drosophila Slit2 gene, has tumor suppressor activity and is frequently inactivated in lung and breast cancers.
Dallol A; Da Silva NF; Viacava P; Minna JD; Bieche I; Maher ER; Latif F
Cancer Res; 2002 Oct; 62(20):5874-80. PubMed ID: 12384551
[TBL] [Abstract][Full Text] [Related]
35. Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing.
Gonzalez-Zulueta M; Bender CM; Yang AS; Nguyen T; Beart RW; Van Tornout JM; Jones PA
Cancer Res; 1995 Oct; 55(20):4531-5. PubMed ID: 7553622
[TBL] [Abstract][Full Text] [Related]
36. Promoter hypermethylation of multiple genes in early gastric adenocarcinoma and precancerous lesions.
Zou XP; Zhang B; Zhang XQ; Chen M; Cao J; Liu WJ
Hum Pathol; 2009 Nov; 40(11):1534-42. PubMed ID: 19695681
[TBL] [Abstract][Full Text] [Related]
37. Epigenetic inactivation of the candidate 3p21.3 suppressor gene BLU in human cancers.
Agathanggelou A; Dallol A; Zöchbauer-Müller S; Morrissey C; Honorio S; Hesson L; Martinsson T; Fong KM; Kuo MJ; Yuen PW; Maher ER; Minna JD; Latif F
Oncogene; 2003 Mar; 22(10):1580-8. PubMed ID: 12629521
[TBL] [Abstract][Full Text] [Related]
38. RASSF1A promoter region CpG island hypermethylation in phaeochromocytomas and neuroblastoma tumours.
Astuti D; Agathanggelou A; Honorio S; Dallol A; Martinsson T; Kogner P; Cummins C; Neumann HP; Voutilainen R; Dahia P; Eng C; Maher ER; Latif F
Oncogene; 2001 Nov; 20(51):7573-7. PubMed ID: 11709729
[TBL] [Abstract][Full Text] [Related]
39. Combination of DNA methylation inhibitor 5-azacytidine and arsenic trioxide has synergistic activity in myeloma.
Chen G; Wang Y; Huang H; Lin F; Wu D; Sun A; Chang H; Feng Y
Eur J Haematol; 2009 Mar; 82(3):176-83. PubMed ID: 19077051
[TBL] [Abstract][Full Text] [Related]
40. Aberrant promoter methylation and silencing of the POU2F3 gene in cervical cancer.
Zhang Z; Huettner PC; Nguyen L; Bidder M; Funk MC; Li J; Rader JS
Oncogene; 2006 Aug; 25(39):5436-45. PubMed ID: 16607278
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]